Ken Griffin Protara Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$1.7 - $2.4 $1,020 - $1,440	600 Added 7.14%	9,000 $16,000
Q2 2024 Aug 14, 2024	BUY	$1.96 - $4.14 $9,016 - $19,044	4,600 Added 121.05%	8,400 $17,000
Q1 2024 May 15, 2024	BUY	$1.86 - $4.83 $6,510 - $16,905	3,500 Added 1166.67%	3,800 $15,000
Q4 2023 Feb 14, 2024	BUY	$1.12 - $1.93 $336 - $579	300 New	300 $0
Q4 2022 Feb 14, 2023	BUY	$2.43 - $3.7 $1,944 - $2,960	800 New	800 $2,000

10.7M

1.8K

Ticker TARA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 11,267,400
Market Cap $26.9M
Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chlorid...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.